I.V. Nicotine for Smoking Addiction
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests an intravenous (IV) nicotine treatment to observe its effects on smokers' brain activity after periods of abstinence. Researchers aim to understand how the brain's receptors respond to nicotine after smokers abstain for one or two nights. The study uses brain scans and nicotine injections to monitor these changes. Smokers who have been smoking at least 10 cigarettes a day for six months and are willing to stay overnight for the study may qualify. As a Phase 1 trial, this research seeks to understand how the treatment works in people, offering participants a unique opportunity to be among the first to receive this new treatment.
Will I have to stop taking my current medications?
Yes, you may need to stop taking certain medications. The trial excludes participants who are currently using or have recently stopped using specific medications like smoking cessation drugs, certain antidepressants, and heart medications. It's best to discuss your current medications with the study team to see if they affect your eligibility.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that nicotine, when administered intravenously, is usually well-tolerated. However, nicotine's addictive nature can lead to dependency if not carefully managed, despite the body's ability to handle it well in controlled settings.
Specific safety data on intravenous nicotine remains limited, as this trial is in its early stages. Researchers are closely examining its safety. Early-phase trials primarily focus on ensuring a treatment's safety for participants, so researchers are carefully monitoring any potential side effects or risks.
The PET/CT scan used with the nicotine infusion is a common imaging method in medical studies and is generally considered safe. These scans help researchers observe how nicotine affects brain activity.
In summary, while nicotine is known to be addictive, the controlled environment and careful monitoring in this trial aim to reduce risks and ensure participant safety.12345Why are researchers excited about this trial's treatments?
Most treatments for smoking addiction involve nicotine replacement therapies, such as patches or gum, or medications like varenicline and bupropion that help reduce cravings. However, intravenous (I.V.) nicotine offers a different approach by delivering nicotine directly into the bloodstream, potentially providing more immediate relief from withdrawal symptoms. This method could help researchers better understand the brain’s response to nicotine and improve the precision of nicotine dosage, leading to more effective treatments. Researchers are excited about this trial because it could uncover new insights into nicotine addiction and pave the way for innovative therapies.
What evidence suggests that this trial's treatments could be effective for smoking addiction?
Studies have shown that nicotine replacement therapies (NRTs) can help people quit smoking. For example, using nicotine in various forms can increase quit rates from 10% to 17%. Research suggests that combining different NRTs might be more effective than using just one type. Although limited data exists on using I.V. nicotine specifically, this trial will explore its potential to provide nicotine to the body and ease withdrawal symptoms. Early signs indicate this approach might reduce the number of cigarettes smoked, potentially aiding in quitting smoking.12367
Are You a Good Fit for This Trial?
Adult smokers aged 18-65 who smoke at least 10 cigarettes a day for the past 6 months and have a carbon monoxide reading over 10 ppm. They must be willing to stay overnight in the hospital and abstain from smoking as required. Pregnant women, heavy alcohol drinkers, those with liver/kidney disease or high blood pressure, or users of certain medications are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
PET/CT Scan Sessions
Participants undergo two separate 7-hour PET/CT scan sessions, one following an overnight abstinence and one following two overnights of abstinence.
Brain MRI
Participants will have a structural Brain MRI performed within 1 year prior to study enrollment or undergo a research Brain MRI after consent.
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- 2-[18F]-FA PET/CT
- I.V. Nicotine
Trial Overview
The study tests how nicotine affects brain receptors in smokers using PET/CT scans after periods of abstinence. Participants will undergo two separate scan sessions with an injection and infusion of a tracer substance followed by IV nicotine during one session to compare receptor uptake before and after nicotine exposure.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Subjects will participate in two separate 10-hour PET/CT Scan Sessions (each with 2 hours of actual PET/CT scanning): one following an overnight abstinence and one following two overnights of abstinence. To achieve and confirm two overnights of abstinence, participants will present to the inpatient CHPS the day prior to the scheduled scan and stay overnight
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Pennsylvania
Lead Sponsor
Published Research Related to This Trial
Citations
Nicotine Addiction and Smoking: Health Effects and ... - NCBI
Rates of smoking cessation may increase from 10% in control groups to 17% in persons using any form of NRT, and using 2 types of NRT is more effective than ...
The relationship between nicotine dependence and ...
A high level of nicotine dependence was recorded for 38 participants (13 %). No significant differences were reported in the participants' characteristics ...
Increased Self-efficacy to Quit and Perceived Control over ...
The results highlight two relatively under-studied potential psychological predictors of abstinence following treatment for nicotine dependence.
Tobacco Addiction
The duration of therapy is usually 8 to 12 weeks; even though most smokers who have a response to nicotine-replacement therapy will quit smoking ...
Integrated Nicotine Replacement and Behavioral Support ...
Main Outcomes and Measures The primary outcome was at least a 50% reduction in the number of cigarettes smoked, self-reported as cigarette use ...
Nicotine Addiction and Smoking: Health Effects and ... - NCBI
The effect of cigarette smoking, alcohol consumption and fruit and vegetable consumption on IVF outcomes: a review and presentation of original data. Reprod ...
Nicotine Dependence Among Adults With Cigarette Use in ...
We found that nicotine dependence prevalence decreased from 59.52% in 2006 to 56.00% in 2019 (difference, 3.52 percentage points; percentage ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.